HomeAKTX • NASDAQ
Akari Therapeutics PLC
add
Market news
TSLA
5.67%
0.93%
0.55%
15.59%
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
(USD) | Mar 2025info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 3.53M | -41.14% |
Net income | -3.71M | 33.44% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -3.52M | 41.07% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
(USD) | Mar 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 2.58M | 97.10% |
Total assets | 50.96M | 1,738.35% |
Total liabilities | 29.21M | 361.87% |
Total equity | 21.75M | — |
Shares outstanding | 32.18M | — |
Price to book | 1.67 | — |
Return on assets | -17.36% | — |
Return on capital | -35.91% | — |
Cash Flow
Net Change in Cash
Net change in cash
(USD) | Mar 2025info | Y/Y change |
---|---|---|
Net income | -3.71M | 33.44% |
Cash from operations | -2.15M | 46.83% |
Cash from investing | — | — |
Cash from financing | 2.13M | 40.89% |
Net change in cash | -17.00K | 99.33% |
Free cash flow | 774.50K | 129.13% |
Previous close
$1.25
Day range
$1.20 - $1.30
Year range
$0.85 - $4.40
Market cap
41.09M USD
Avg Volume
14.23K
Primary exchange
NASDAQ
About
Founded
2004
Headquarters
Website
Employees
8